Holen Sie sich die Stockscreener-App
40.98
0.86%
0.35
Schlusskurs vom Vortag:
$40.63
Offen:
$41
24-Stunden-Volumen:
1.00M
Relative Volume:
0.90
Marktkapitalisierung:
$3.00B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-98.78M
KGV:
-24.63
EPS:
-1.6638
Netto-Cashflow:
$-65.60M
1W Leistung:
-12.75%
1M Leistung:
-28.67%
6M Leistung:
-10.11%
1J Leistung:
+92.48%
1-Tages-Spanne:
$40.29
$42.06
1-Wochen-Bereich:
$39.25
$46.94
52-Wochen-Spanne:
$14.79
$62.32
Enliven Therapeutics Inc Stock (ELVN) Company Profile
Firmenname
Enliven Therapeutics Inc
Sektor
Branche
Telefon
720-647-8519
Adresse
6200 LOOKOUT ROAD, BOULDER
Compare ELVN vs VRTX, MRNA, REGN, ARGX, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ELVN
Enliven Therapeutics Inc
|
40.98 | 3.28B | 0 | -98.78M | -65.60M | -1.6638 |
VRTX
Vertex Pharmaceuticals Inc
|
510.08 | 127.93B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
225.00 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
746.54 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
825.03 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
189.76 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Enliven Therapeutics Inc Stock (ELVN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-16 | Eingeleitet | Goldman | Buy |
| 2024-12-13 | Eingeleitet | BTIG Research | Buy |
| 2024-09-09 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-06-11 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-04-09 | Eingeleitet | Mizuho | Buy |
| 2023-03-29 | Eingeleitet | Jefferies | Buy |
Alle ansehen
Enliven Therapeutics Inc Aktie (ELVN) Neueste Nachrichten
Director Jeffrey Garland proposes selling 13,000 Enliven Therapeutics (NASDAQ: ELVN) shares. - Stock Titan
ELVN Initiated Coverage by JP Morgan -- Rating Set to Overweight - GuruFocus
JPMorgan Initiates Enliven Therapeutics at Overweight With $75 Price Target - marketscreener.com
Enliven Therapeutics stock initiated at Overweight by JPMorgan - Investing.com Canada
Understanding the Setup: (ELVN) and Scalable Risk - Stock Traders Daily
ELVN Stock On Track For Best Week Since March Following FDA-Aligned Path For Cancer Drug Development - Stocktwits
Enliven Therapeutics CMO Helen Collins sells $251k in shares By Investing.com - Investing.com South Africa
Enliven Therapeutics CFO Benjamin Hohl sells $303,003 in stock By Investing.com - Investing.com South Africa
Enliven Therapeutics CFO Benjamin Hohl sells $303,003 in stock - Investing.com
Enliven Therapeutics CFO Completes Stock Option Exercise and Multi-Tranche Stock Sales - kalkinemedia.com
Enliven Therapeutics Insider Sold Shares Worth $251,754, According to a Recent SEC Filing - marketscreener.com
Enliven Therapeutics Insider Sold Shares Worth $303,003, According to a Recent SEC Filing - Yahoo Finance
Enliven Therapeutics (ELVN) CFO exercises options, sells 6,018 shares - Stock Titan
Enliven Therapeutics, Inc. (ELVN) Stock Analysis: Biotech Innovator with a 47% Upside Potential - DirectorsTalk Interviews
Enliven Therapeutics (ELVN) officer lines up new stock sale - Stock Titan
Transcript : Enliven Therapeutics, Inc. Presents at Morgan Stanley 24th Annual Global Healthcare Conference, Sep-16-2026 11 - marketscreener.com
ELVN: ELVN-001 targets a $16B global CML market with best-in-class efficacy and strong clinical momentum - TradingView
Enliven Therapeutics at Morgan Stanley conference: cash, trials and CML By Investing.com - Investing.com Canada
ELVN: ELVN-001 targets major CML market segments with strong clinical and commercial differentiation - TradingView
(ELVN) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Chronic Myeloid Leukemia Clinical Trial Pipeline Appears Robust With 25+ Key Pharma Companies Actively Working in the Domain | DelveInsight - GlobeNewswire Inc.
Planned stock sale at Enliven Therapeutics (NASDAQ: ELVN) tops the million-dollar mark - Stock Titan
Enliven's Morgan Stanley conference chat will be webcast Sept. 16 - Stock Titan
Enliven Therapeutics to Present at Upcoming Investor Conferences - PR Newswire
Enliven Therapeutics: A Clean Active-Site TKI Could Redefine CML Sequencing (NASDAQ:ELVN) - Seeking Alpha
Enliven Therapeutics Announces Oral and Poster Presentations at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting - PR Newswire
Discipline and Rules-Based Execution in ELVN Response - Stock Traders Daily
Enliven Therapeutics Presents ELVN-001 Data at SOHO Annual Meeting - Intellectia AI
Analysts Are Bullish on Top Healthcare Stocks: Enliven Therapeutics (ELVN), Argenx Se (ARGX) - The Globe and Mail
Enliven Therapeutics Inc. (NASDAQ: ELVN) Share Price, ELVN Stock News, ELVN Share Price & Updates - kalkine.ca
Enliven (ELVN) Earnings Snapshot: EPS Falls Short of Its Estimate in the Reported Period; Share Response: The Stock Records a 0.79% Decrease on the DayProfit Cycle Analysis - vinanet.vn
Handelsbanken Fonder AB Buys New Shares in Enliven Therapeutics, Inc. $ELVN - MarketBeat
Enliven Therapeutics CFO Benjamin Hohl Executes Two Stock Sales on August 17 Under 10b5-1 Plan - Kalkine Media
Benjamin Hohl Sells 6,018 Shares of Enliven Therapeutics (NASDAQ:ELVN) Stock - MarketBeat
Enliven (NASDAQ: ELVN) CFO sells 6,018 shares in 10b5-1 plan - Stock Titan
Enliven Therapeutics (ELVN) CMO exercises options, sells stock - Stock Titan
Enliven’s Lead Drug Could Disrupt The Leukemia Treatment Market, Analyst Says - Sahm
Barclays Initiates Enliven Therapeutics at Overweight With $78 Price Target - Moomoo
Enliven Therapeutics CMO Helen Louise Collins Executes Stock Option and Sells 5,000 Shares Under 10b5-1 Plan - Kalkine Media
Enliven Therapeutics, Inc. /US/ Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs
What's Going On With Enliven Therapeutics Stock Tuesday?Enliven Therapeutics (NASDAQ:ELVN) - Benzinga
Enliven a new outperform at Barclays on potential of CML asset - Seeking Alpha
Enliven Therapeutics (NASDAQ:ELVN) Now Covered by Analysts at William Blair - MarketBeat
Enliven Therapeutics (NASDAQ:ELVN) Now Covered by Barclays - MarketBeat
Enliven Therapeutics (NASDAQ:ELVN) Given New $73.00 Price Target at Mizuho - MarketBeat
Barclays initiates Enliven Therapeutics stock at Overweight, $78 PT By Investing.com - Investing.com Canada
William Blair Initiates Enliven Therapeutics at Outperform - marketscreener.com
William Blair initiates Enliven Therapeutics stock with outperform rating By Investing.com - Investing.com Canada
261,344 Shares in Enliven Therapeutics, Inc. $ELVN Acquired by TimesSquare Capital Management LLC - MarketBeat
Mizuho Raises Price Target on Enliven Therapeutics to $73 From $62, Keeps Outperform Rating - Yahoo Finance
symbol__ Stock Quote Price and Forecast - CNN
Finanzdaten der Enliven Therapeutics Inc-Aktie (ELVN)
Umsatz
Nettogewinn
Free Cashflow
ENV
Enliven Therapeutics Inc-Aktie (ELVN) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Garland J. Scott | Director |
Oct 01 '26 |
Sale |
46.67 |
13,000 |
606,719 |
0 |
5.32%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):